Project Update

Futura Medical PLC 09 April 2008 For Immediate Release 9 April 2008 Futura Medical Plc ('Futura' or 'the Company') Update on topical pain relief project Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, can provide the following update on its topical pain relief project, TPR100, using Futura's proprietary trans-dermal delivery technology, DermaSys(R). Completion of clinical studies to evaluate drug delivery using Futura's Dermasys (R) technology has been extended to complete formulation optimisation. Commercial negotiations are continuing on a non-exclusive basis. We will provide further updates to shareholders at the earliest opportunity. For further information: Futura Medical plc James Barder, Chief Executive Tel: +44 (0) 1483 685 670 mail to: www.futuramedical.co.uk james.barder@futuramedical.co.uk Canaccord Adams Ryan Gaffney / Adria Da Breo Tel: +44 (0) 20 7050 6500 Media enquiries: Buchanan Communications Mark Court / Rebecca Skye Dietrich Tel: +44 (0) 020 7466 5000 Notes to Editors Futura Medical plc Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups. Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.co.uk This information is provided by RNS The company news service from the London Stock Exchange